BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8351927)

  • 21. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined effect of a low fat diet and doxazosin on blood pressure control and blood lipids. Hunter Hypertension Research Group.
    J Hum Hypertens; 1994 Dec; 8(12):907-10. PubMed ID: 7884789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
    Daae LN; Kierulf P; Brusletto B; Westheim A; Holme I; Syvertsen JO
    Tidsskr Nor Laegeforen; 1991 Apr; 111(9):1102-5. PubMed ID: 1827216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
    Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
    Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Chapman N; Chang CL; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Circulation; 2008 Jul; 118(1):42-8. PubMed ID: 18559700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
    Yasuda G; Hasegawa K; Kuji T; Ogawa N; Shimura G; Umemura S; Tochikubo O
    Diabet Med; 2005 Oct; 22(10):1394-400. PubMed ID: 16176202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age dependence of therapy result and risk in the treatment of arterial hypertension?
    Höffler D; Morgenstern HO
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S184-8. PubMed ID: 11527125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group.
    Joglekar SJ; Nanivadekar AS
    J Assoc Physicians India; 1998; Suppl 1():52-62. PubMed ID: 11233387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
    Krupicka J; Ceypová K; Kristenová P; Hauser T
    Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of baseline values. II: Variations in plasma lipoprotein fractions during doxazosin treatment for hypertension.
    Ahaneku JE; Taylor GO; Agbedana EO
    Int J Clin Pharmacol Res; 1998; 18(4):165-70. PubMed ID: 10052026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension.
    Ceral J; Solar M
    Blood Press; 2009; 18(1-2):74-7. PubMed ID: 19353415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fosinopril on the blood pressure and lipid profile of patients undergoing heart transplantation.
    Almenar L; Osa A; Palencia M; Flores A; Sánchez E
    J Heart Lung Transplant; 1997 Apr; 16(4):454-9. PubMed ID: 9154957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
    Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
    Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
    Daae LN; Westlie L
    Blood Press; 1998 Jan; 7(1):39-45. PubMed ID: 9551876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.